中国P站

Platelet-to-Lymphocyte Ratio Might Predict the Response to Dupilumab Treatment for Patients with Nasal Polyposis

Received Date: Feb 28, 2025 / Published Date: Mar 30, 2025

Citation: Andrew B (2025) Platelet-To-Lymphocyte Ratio Might Predict the Response to Dupilumab Treatment for Patients with Nasal Polyposis. Otolaryngol (Sunnyvale) 15: 629.DOI: 10.4172/2161-119X.1000629

Copyright: © 2025 Andrew B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a debilitating inflammatory condition often resistant to conventional therapies, necessitating innovative treatment approaches such as biologics like dupilumab. Dupilumab, a monoclonal antibody targeting interleukin-4 receptor alpha, has demonstrated efficacy in reducing nasal polyp burden, yet response variability among patients highlights the need for predictive biomarkers. The platelet-to-lymphocyte ratio (PLR), a simple hematological marker of systemic inflammation, has emerged as a potential predictor of treatment outcomes in various inflammatory diseases. This study explores the hypothesis that pretreatment PLR might predict the response to dupilumab in CRSwNP patients. We conducted a retrospective analysis of 65 patients with CRSwNP treated with dupilumab, assessing pretreatment PLR and its association with total treatment response, defined as a post-treatment nasal polyp score (NPS) of 0. Results indicated that patients with a high PLR (>131.2) exhibited a 3.9-fold higher likelihood of achieving complete polyp resolution, independent of confounding factors such as age, sex, and comorbidities. These findings suggest that PLR could serve as a costeffective, accessible biomarker to stratify patients likely to benefit from dupilumab, though prospective validation is warranted to confirm its clinical utility.